Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer

B. Klein, E. Sadikov, M. Mishaeli, I. Levin, A. Figer

Research output: Contribution to journalReview articlepeer-review

Abstract

Gemcitabine has been recently added to the 5-fluorouracil (5-FU) protocol in the treatment of both new and 5-FU refractory patients with pancreatic cancer. We compared the efficacy of gemcitabine versus 5-FU and leucovorin (LCV) in 82 patients with advanced pancreatic cancer. Forty-seven patients received 5-FU and LCV and 35 patients received gemcitabine. Objective responses were documented in 4% on the 5-FU and LCV arm, compared to 9% in the gemcitabine arm. No change was observed in 48% on the 5-FU and LCV arm compared to 20% in the gemcitabine arm. Clinical benefit was observed in 19% on the 5-FU and LCV arm compared to 48% in the gemcitabine arm (p<0.001). Toxicity was mild and well tolerated in both arms. One-year survival was 32% on the 5-FU and LCV arm and 23% in the gemcitabine arm. These results indicate that gemcitabine had a significantly higher clinical benefit than 5-FU and should be the standard treatment in advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)875-877
Number of pages3
JournalOncology Reports
Volume7
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Keywords

  • 5-FU
  • Gemcitabine
  • Leukovorin
  • Pancreatic cancer

Fingerprint

Dive into the research topics of 'Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer'. Together they form a unique fingerprint.

Cite this